PLIANT THERAPEUTICS, INC. - 10-Q Filing
Pliant Therapeutics filed its quarterly report for March 31, 2026, disclosing unaudited financial results. The company reported a net loss of $45.8 million for the first quarter compared to a net loss of $47.9 million in the same period last year. Total operating expenses were $45.8 million versus $47.9 million YoY.
Tickers: $PLRX